Custom MHC Class II HLA-DP Xynapse and Dextramer R

The National Cancer Institute (NCI) is seeking custom MHC Class II HLA-DP Xynapse and Dextramer reagents for liver cancer neoantigen validation. The proposed contractor is Immudex USA, LLC/Immudex ApS, which is uniquely qualified to provide the required reagents due to its proprietary technology, manufacturing capability, and specialized expertise. The Government is unaware of any other source capable of providing equivalent custom Dextramer reagents. • The custom reagents are for liver cancer neoantigen validation • Immudex USA, LLC/Immudex ApS is the proposed contractor • The Government is seeking capability statements from other sources to determine if a competitive procurement should be conducted